Literature DB >> 14622493

Muscarinic receptors: what we know.

Harriette M Scarpero1, Roger R Dmochowski.   

Abstract

An understanding of muscarinic receptors is tantamount to an understanding of overactive bladder. The M(3) muscarinic receptor subtype is responsible for detrusor smooth muscle contraction and it exerts an exocrine function in the salivary glands. Alterations in the receptor's response to acetylcholine as a result of injury may lead to hypersensitivity and overactivity. The M(2) receptor subtype, which is mainly responsible for cardiac function, is the muscarinic receptor of highest proportion in the detrusor. M(2) also may play a role in detrusor contraction in injury and pathologic states. Muscarinic antagonists are the mainstay of pharmacotherapy for overactive bladder, but those that are available are not tissue specific. Growing knowledge of the nuances of receptor-ligand behavior and interaction between muscarinic receptors subtypes may provide novel targets for future drug development, improve efficacy, and reduce bothersome side effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14622493     DOI: 10.1007/s11934-003-0021-3

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  53 in total

Review 1.  International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

Authors:  M P Caulfield; N J Birdsall
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

2.  Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder.

Authors:  R G Charlton; A R Morley; P Chambers; J I Gillespie
Journal:  BJU Int       Date:  1999-12       Impact factor: 5.588

3.  Muscarinic cholinergic receptor subtypes in rat sublingual glands.

Authors:  G E Watson; D J Culp
Journal:  Am J Physiol       Date:  1994-02

4.  Urothelium derived inhibitory factor and cross-talk among receptors in the trigone of the bladder of the pig.

Authors:  L Templeman; C R Chapple; R Chess-Williams
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

5.  Dependency of detrusor contractions on calcium sensitization and calcium entry through LOE-908-sensitive channels.

Authors:  J R Jezior; J D Brady; D I Rosenstein; K A McCammon; A S Miner; P H Ratz
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

6.  Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo.

Authors:  S S Hegde; A Choppin; D Bonhaus; S Briaud; M Loeb; T M Moy; D Loury; R M Eglen
Journal:  Br J Pharmacol       Date:  1997-04       Impact factor: 8.739

7.  Evidence for inhibitory nicotinic and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder.

Authors:  G T Somogyi; W C de Groat
Journal:  J Auton Nerv Syst       Date:  1992-02

8.  Change in muscarinic modulation of transmitter release in the rat urinary bladder after spinal cord injury.

Authors:  George T Somogyi; Ganna V Zernova; Mitsuharu Yoshiyama; Jeova N Rocha; Christopher P Smith; William C de Groat
Journal:  Neurochem Int       Date:  2003-07       Impact factor: 3.921

Review 9.  Muscarinic antagonists in development for disorders of smooth muscle function.

Authors:  R M Wallis; C M Napier
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

Review 10.  Current and future pharmacological treatment for overactive bladder.

Authors:  Naoki Yoshimura; Michael B Chancellor
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

View more
  11 in total

1.  Management of overactive bladder with transdermal oxybutynin.

Authors:  Jonathan S Starkman; Roger R Dmochowski
Journal:  Rev Urol       Date:  2006

2.  [Characteristic changes in the pattern of distribution of muscarinic receptors in the exstrophic bladder wall].

Authors:  W H Rösch; M Hagemann; I Hanisch; W L Neuhuber
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 3.  The puzzle of overactive bladder: controversies, inconsistencies, and insights.

Authors:  Roger R Dmochowski
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-06-27

4.  Inhibition of ligand binding to G protein-coupled receptors by arachidonic acid.

Authors:  Elizabeth Z Bordayo; John R Fawcett; Sarita Lagalwar; Aleta L Svitak; William H Frey
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

Review 5.  Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.

Authors:  Hashim Hashim; Paul Abrams
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  The Q-T interval and antimuscarinic drugs.

Authors:  Roger Dmochowski; David R Staskin
Journal:  Curr Urol Rep       Date:  2005-11       Impact factor: 2.862

7.  Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.

Authors:  Tondalaya Gamble; Peter Sand
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

Review 8.  Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.

Authors:  Richard T Kershen; Mike Hsieh
Journal:  Curr Urol Rep       Date:  2004-10       Impact factor: 2.862

Review 9.  Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects.

Authors:  Adam P Klausner; William D Steers
Journal:  Curr Urol Rep       Date:  2007-11       Impact factor: 2.862

Review 10.  Update on the management of overactive bladder: patient considerations and adherence.

Authors:  Alex Gomelsky; Roger R Dmochowski
Journal:  Open Access J Urol       Date:  2010-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.